Consistent Cardiovascular (CV) Benefit of Empagliflozin Over the Spectrum of CV Risk Factor Control in EMPA-REG OUTCOME
Metabolism: Clinical and Experimental - Netherlands
doi 10.1016/j.metabol.2019.12.071
Full Text
Open PDFAbstract
Available in full text
Date
March 1, 2020
Authors
Publisher
Elsevier BV